deal-signal?condition=Disease+area+%E2%80%94+e.g.+%22Obesity%22+%7C+%22Cardiovascular%22+%7C+%22Oncology%22+%7C+%22Rare+Neurological%22+%7C+%22Autoimmune%22&deal_type=acquisition+%7C+licensing+%7C+both+%28default%3A+both%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&stage=phase2+%7C+phase3+%7C+both+%28default%3A+both%29

Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples…

Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.

UNRATEDDelisted

Overview

Grade?

UNRATED

0 of 30 paid calls toward a letter

Price

$0.35 per call

Paid calls

none yet

delivery unknown until someone pays

More info

Seller?

0x50ab2018…284912fc

URL

https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal?condition=Disease+area+%E2%80%94+e.g.+%22Obesity%22+%7C+%22Cardiovascular%22+%7C+%22Oncology%22+%7C+%22Rare+Neurological%22+%7C+%22Autoimmune%22&deal_type=acquisition+%7C+licensing+%7C+both+%28default%3A+both%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&stage=phase2+%7C+phase3+%7C+both+%28default%3A+both%29

Seen

first 35 days ago · last 15 days ago

53 free handshakes

Payment

Pays through

x402

Offered on?

algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k, Polygon, eip155:143, eip155:196, Arbitrum, eip155:480, eip155:56, Base USDC, eip155:999, Solana, xrpl:0

Listed on?

Polygon, Arbitrum, Base, Solana

Score, from free handshakes onlyweights 2026.09.5

UN
RATED

0.728 liveness verified, no letter

To a letter · 30 paid calls

0 of 30

Held down by latency p95 · gap to 1.000 is 0.272: 0.072 uncertain ? + 0.200 short ? · 0.072 to B

How the composite of 0.728 is made up, part by part
Component	Weight	Measured	Lower bound ?		Adds	Short ?	Uncertain ?
latency p95costs the most it answered as fast as its class	0.20	0.00	0.000		0.000	−0.200	0
liveness it answered at all	0.60	1.00	0.879		0.528	0	−0.072
price stability the price stayed where it was listed	0.20	1.00	1.000		0.200	0	0
Composite	1.00		0.728	gap to 1.000 = 0.272 · 0.200 short · 0.072 uncertain	0.728	−0.200	−0.072

Not measured: correctness · nobody paid; honesty · nobody paid; schema conformance · no answer had a published shape to check

The multiplication, written out

  0.200 × 0.000   latency p95    
+ 0.600 × 0.879   liveness       
+ 0.200 × 1.000   price stability
= 0.728           → UNRATED: 51 of 30 paid calls      weights 2026.09.5 · 51 samples · seed cap_01M1A51TFGNRR70R9H3BX5X366|2026-08-27T00:51:40.247Z|2026.09.5

Verify it yourself

npx teppi-check https://clinicalintelpulse.theaslangroupllc.com/api/clinical/deal-signal?condition=Disease+area+%E2%80%94+e.g.+%22Obesity%22+%7C+%22Cardiovascular%22+%7C+%22Oncology%22+%7C+%22Rare+Neurological%22+%7C+%22Autoimmune%22&deal_type=acquisition+%7C+licensing+%7C+both+%28default%3A+both%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&stage=phase2+%7C+phase3+%7C+both+%28default%3A+both%29

curl -s https://api.teppi.xyz/v1/trust/cap_01M1A51TFGNRR70R9H3BX5X366